# Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

> **NCT01254864** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 190 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** Sunitinib
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01254864
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-16
- **Primary completion:** 2023-12-07
- **Final completion:** 2023-12-07
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254864, "Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01254864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*